Paboxinib is a targeted drug that inhibits the proliferation of cancer cells and is a relatively new drug, so far an oral preparation. To a certain extent, this drug is able to inhibit the progression of cancer cells and inhibit the proliferation and increase of cancer cells and tumor cells. It is more commonly used clinically for, for example, breast cancer that has metastasized due to bronchial lung cancer, alveolar cell carcinoma, etc. It has a strong therapeutic effect. It can improve patients’ survival time, quality of life, prolong their life cycle and reduce their pain. The pharmacological mechanism of this drug is mainly to inhibit the growth of cancer cells and promote the apoptosis of cancer cells. Some patients may experience some side effects during the course of taking this drug, and may experience a slight decrease of granulocytes in white blood cells.